| Description |
| Product Type |
Product Size |
| Capsules |
20'S |
| Product Company |
| Brookes Pharmaceutical |
Diclofenac sodium 100mg |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Sami Pharmaceutical |
Diclofenac Sodium 75mg |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
AJM Pharmaceuticals |
|
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Aqvida |
|
| Product Type |
Product Size |
| Injection
|
6'S |
| Product Company |
| Chiesi Pharmaceuticals |
Meglumine indomethicinate 77.2+50mg
|
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Sandoz |
|
| Content | The Sustain Release tablet form of diclofenac is used to reduce pain, swelling (inflammation), and joint stiffness from arthritis. | Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. | Gemcitabine is a nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer. | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. | Indomethacin is an anti-inflammatory agent, used to combat pain and inflammation in various conditions
| Oxaliplatin is a platinum based chemotherapy agent used to treat carcinoma of the colon or rectum or stage III colon cancer. |
Reviews
There are no reviews yet.